Navigation

🏠 Home 📰 Latest News 🌍 World 🇮🇳 India 💼 Business 💻 Technology ⚽ Sports 🎬 Entertainment 🏥 Health
Biggest News Aggregation in the World
📰 Pre Clinical Data News

Pre Clinical Data News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Pre Clinical Data. Real-time updates on events, politics, business and more.

Cytokinetics Provides Update on Cardiac Myosin Inhibitor Programs and Plans to Build a Specialty Cardiology Franchise at Virtual Investor & Analyst Day

October 19, 2023
New Long-Term Data from FOREST-HCM, the Open-Label Extension Study of Aficamten,Show Sustained Improvements in Clinical Efficacy Endpointsand No Treatment Interruptions for Low Ejection Fraction ...
San Francisco United States Theodore Abraham Roberti Blum Diane Weiser Cytokinetics Incorporated Nasdaq
Source: marketscreener.com

Geron Presentations at Upcoming EHA Annual Meeting to Report Updated Durability, Disease Modification and Favorable Patient Reported Outcomes (PRO) in Imetelstat-Treated Lower Risk MDS Patients in IMerge Phase 3

May 11, 2023
Longer follow-up data for 1-year transfusion independence in IMerge Phase 3, which demonstrated statistically significant and clinically meaningful continuous, durable efficacy Strong... | May 11, 2023
France General United States Faye Feller Nicolas Chatain Mikkael Sekeres Nicolas Chapuis
Source: marketscreener.com

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

Geron Corporation: Geron Presentations at Upcoming EHA Annual Meeting to Report Updated Durability, Disease Modification and Favorable Patient Reported Outcomes (PRO) in Imetelstat-Treated Lower Risk MDS Patients in IMerge Phase 3

May 11, 2023
Longer follow-up data for 1-year transfusion independence (TI) in IMerge Phase 3, which demonstrated statistically significant and clinically meaningful continuous, durable efficacy Strong
France General United States Nicolas Chatain Faye Feller Uwe Platzbecker Valeria Santini
Source: finanznachrichten.de

Moderna, Inc.: Moderna Receives FDA Emergency Use Authorization for Omicron-Targeting Bivalent COVID-19 Booster Vaccine in Children 6 Months Through 5 Years of Age

December 8, 2022
MRNA-1273.222 Targets the BA.4/BA.5 Strains of Omicron VariantAuthorization Is Based Upon Clinical and Pre-Clinical Data for Moderna's Bivalent VaccinesCAMBRIDGE, MA / ACCESSWIRE / December 8, 2022 / Moderna
United Kingdom Lavina Talukdar Chris Ridley Exchange Commission Moderna Inc View Corporate Communications
Source: finanznachrichten.de

Moderna, Inc.: Moderna Receives FDA Authorization for Emergency Use of Omicron-Targeting Bivalent COVID-19 Booster Vaccine for Children and Adolescents 6 to 17 Years of Age

October 12, 2022
MRNA-1273.222 Targets the BA.4/BA.5 Strains of Omicron VariantAuthorization Is Based Upon Clinical and Pre-Clinical Data for Moderna's Bivalent Vaccine CandidatesCAMBRIDGE, MA / ACCESSWIRE / October 12
United Kingdom Elise Meyer Lavina Talukdar Exchange Commission Corporate Communications Moderna Inc
Source: finanznachrichten.de

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science